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Abstract
Background: The US National Cancer Institute (NCI) has developed the Patient-Reported Outcomes version of the
Common Terminology Criteria for Adverse Events (PRO-CTCAE) to capture patients’ self-reported symptomatic adverse
events in cancer clinical trials. The aim of this study was to develop and linguistically validate a Japanese translation of
PRO-CTCAE. Forward- and back-translations were produced, and an independent review was performed by the Japan
Clinical Oncology Group (JCOG) Executive Committee and the US NCI. We then conducted cognitive interviews with
21 patients undergoing cancer treatment. Participants were asked to complete the PRO-CTCAE and were interviewed
using semi-structured scripts and predetermined probes to investigate whether any items were difficult to understand
or answer. The interviews were recorded and transcribed, and a thematic analysis was performed. The data were split
into two categories: 1) remarks on the items and 2) remarks on the questionnaire in general.
Results: Twenty-one cancer patients undergoing chemotherapy or hormone therapy were interviewed at the University
of Tokyo Hospital and the Kansai Medical University Hirakata Hospital during 2011 and 2012. Thirty-three PRO-CTCAE
items were evaluated as “difficult to understand,” and 65 items were evaluated as “difficult to answer” by at least one
respondent. However, on further investigation, only 24 remarks were categorized as “comprehension difficulties” or
“clarity” issues. Most of these remarks concerned patients’ difficulties with rating their experience of individual
symptomatic events.
Conclusions: The study provides preliminary evidence supporting the linguistic validity of the Japanese version
of PRO-CTCAE. Further cognitive interviewing is warranted for PRO-CTCAE items relating to sexuality and
anxiety and for response options on severity attribute items.
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Background
The US National Cancer Institute (NCI) Common Toxicity
Criteria for Adverse Events (CTCAE) is a longstanding
grading system widely used for evaluating an array of
adverse events in cancer treatment. There is a growing
awareness of the importance of patients’ self-reporting of
symptoms using patient-reported outcome (PRO) tools in
addition to professional assessments [1–3]. In order to im-
prove the accuracy and efficiency of collecting and grading
adverse event data, the NCI has established the Patient-
Reported Outcomes version of the Common Terminology
Criteria for Adverse Events (PRO-CTCAE) measurement
system [4–7]. The PRO-CTCAE item library contains
124 items reflecting 78 symptomatic adverse events
drawn from the CTCAE version 4.0. The PRO-
CTCAE was developed to be used in conjunction
with the CTCAE [7]. PRO-CTCAE symptom attri-
butes include frequency (F) (e.g., “In the last 7 days,
how often did you have nausea?”), severity (S) (e.g.,
“In the last 7 days, what was the severity of your
pain?”), interference with daily activities (I) (e.g.,
“How much did fatigue interfere with your usual or
daily activities?”), and presence/absence/amount (P)
(e.g., “In the last 7 days, did you have any bed
sores?”). PRO-CTCAE scores range from 0 to 4, cor-
responding to the response choices. The recall period
for each question is the previous 7 days [8]. Content
validation and a psychometric evaluation of the PRO-
CTCAE measurement system have already been
performed [6, 9] and their feasibility investigated in a mul-
ticenter oncology trial [10]. In addition, cognitive
interview-based validation was performed in an
adolescents-with-cancer population [11] and a pediatric
and prosy version of the PRO-CTCAE is also being devel-
oped [12]. As part of the development of PRO-CTCAE,
the NCI has collaborated on the development of versions
of PRO-CTCAE in multiple other languages, such as
Spanish [13], German [14], and Danish [15] language
versions. A Japanese-language version was also created, in
a joint endeavor by Tohoku University, The University of
Tokyo, and the Japan Clinical Oncology Group (JCOG).
The purpose of the Japanese translation is to encourage
the use of PRO-CTCAE among Japanese-speaking cancer
patients living in the USA, as well as those in Japan [16].
Estimated cancer incidence in Japan in 2016 was ap-
proximately one million, and estimated cancer deaths
were 374,000. It is estimated that one in two Japanese
will be diagnosed with cancer during their lifetime [17].
Accessing subjective symptoms of Japanese cancer pa-
tients by self-report has come to be viewed as important
as the objective clinical endpoints such as response rate,
disease-free survival, and overall survival [18]. The aim
of this study was to translate the PRO-CTCAE into
Japanese and linguistically validate the Japanese version.
Linguistic validation
The term “linguistic validation” often refers to the process
of investigating the conceptual equivalence and content
validity of translation of PRO instruments, including for-
ward- and back-translation, review, harmonization, and
cognitive debriefing [19, 20]; it does not include psycho-
metric validation, which is nonetheless seen as an import-
ant second step for cross-cultural validation [21]. This
linguistic validation study is part of a cross-cultural valid-
ation; psychometric evaluation was conducted in another
study with a different 180 participants (UMIN CTR:
UMIN000015169). The results of psychometric validation
are beyond the scope of the current report and will be
presented separately.
Methods
Translation procedure
The PRO-CTCAE questionnaire was translated into
Japanese following the guidance of the International
Society for Pharmacoeconomics and Outcomes
Research (ISPOR) on the “Translation and Cultural
Adaptation Process for PRO Measures” [20]. Two
forward-translations were independently produced by
two native-Japanese-speaking language professionals,
after which a single reconciled version was created by
the project manager and these two translators. Two
native English-speakers who are fluent in Japanese
then produced independent back-translations. An in-
dependent review was performed by the JCOG Execu-
tive Committee, and the finalized Japanese translation
was reviewed and approved by a bilingual medical
oncologist at the US NCI.
Participants and setting
Patients were eligible for the study if they were 18 years
of age or older; had been diagnosed with cancer; were
receiving or had received chemotherapy, radiotherapy,
or hormone therapy within the past 6 months at one of
the study sites; and were able to read, write, and answer
survey items and interview questions verbally in
Japanese as their first language.
Patients were excluded if the physician determined
that they had cognitive impairments or were incapable
of participating in the study. Patients were recruited at
the Kansai Medical University Hirakata Hospital and
The University of Tokyo Hospital. Regarding the
sample size determination, as a literature review of
guidelines suggested that the required sample size of
cognitive interviews for translation of HQOL ques-
tionnaire is around 5 to 15 [19], we aimed to include
more than 16 patients while reflecting differences in
cancer type, gender, regional characteristics, and
educational background.
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Cognitive interview goal and procedure
In total, 123 translated items were divided into two
questionnaires (A and B) per symptom, to reduce
participant burden. Although the PRO-CTCAE library
consists of 124 items, the item “vaginal dryness” was not
included in the cognitive interviews as it was a sexually
sensitive question. As six items are gender-specific, two
versions of each questionnaire were prepared. Further-
more, six symptoms (nine items) were shifted from
questionnaire A to B when the cognitive interviews took
place at the University of Tokyo Hospital to minimize
the item number imbalance between questionnaires; a
total of eight questionnaires were prepared for the cog-
nitive interviews. Each questionnaire consists of about
61 items on average (50 items at minimum and 68 at
maximum).
The cognitive interviews were conducted by master’s-
level psychologists with field experience. The following
study procedures were followed: 1) investigators at the
site screened patients based on the eligibility criteria; 2)
interviewers explained the details of the study to partici-
pants and obtained informed consent; 3) interviewers
scheduled interviews; 4) on the day of the interview,
interviewers reconfirmed participants’ willingness to
participate; 5) participants were asked to fill out a
gender-specific questionnaire; and 6) one-on-one semi-
structured interviews were conducted.
Participants were asked to self-complete the PRO-
CTCAE and make remarks on the items and response op-
tions they evaluated as “difficult to understand” or “diffi-
cult to answer” regarding: 1) comprehensibility; 2) clarity;
3) knowledge and recall (ease of memory retrieval); and 4)
judgment (adequacy of response options). Participants
were then interviewed using semi-structured scripts and
predetermined probes to investigate any items that were
difficult to comprehend if the response choices and recall
period were clear and relevant to their experiences. Reluc-
tance or hesitation to answer and spontaneous questions,
responses, or facial expressions while answering were also
observed by the interviewer. The interviews took place in
a private room.
Analytical approach
We conducted a qualitative-descriptive analysis using
semi-structured cognitive interviews. The interviews were
transcribed word-for-word, examined repeatedly, and
categorized. Remarks were split into two categories: 1) re-
marks on the items and 2) remarks on the questionnaire
in general. The remarks on the items were further catego-
rized into those concerning 1) comprehension difficulties,
2) clarity, 3) knowledge and recall (ease of memory re-
trieval), and 4) ease of judgment and other spontaneous
comments. The remarks on the questionnaire were also
further categorized into those concerning 1) attributes, 2)
ease of memory retrieval and judgment, 3) other remarks
on the questionnaire, and 4) other remarks in general. As
a single patient could make several remarks, the total
number of remarks does not reflect the number of pa-
tients. We performed descriptive statistics to summarize
the variables for the cognitive interviews.
Results
Translation procedure
Comparing the two independent forward-translations,
52 of 80 PRO-CTCAE symptom terms were fully agreed
upon or conceptually equivalent. In the reconciliation
process, the term “how often” in the frequency attribute
items was altered so as not to be directly expressed, due
to an element of the Japanese cultural background. In
Japanese custom, asking about frequency of symptoms
before asking about the presence of symptoms, that is,
assuming their presence, is unnatural and impolite. The
use of “how often” was flagged by the JCOG executive
committee review, and so in the further revision process,
we agreed to not translate “how often” directly in the
question but instead to refer to “frequency” in the re-
sponse options. For severity attribute items, translation
of “its worst” became a discussion topic during the
forward-translation reconciliation process. In Japanese,
there are objective and subjective terms corresponding
to the term “its worst”; for the test script, we changed
“its worst” to “hidoi,” which is an objective term, and
further solicited opinions on two options in the cogni-
tive interviews. In the review by the bilingual medical
oncologist from NCI, there were no major suggestions
for change. One minor suggestion was made to add sup-
plementary explanation to the “radiation skin reaction”
item indicating that this question is intended for cancer
patients receiving radiation therapy.
Cognitive interviews
A total of 21 cancer patients (six males and 15 females)
participated in interviews at either the University of Tokyo
Hospital or the Kansai Medical University Hirakata Hos-
pital between August 2011 and April 2012. Table 1 shows
the clinical and demographic characteristics of the partici-
pants. The patients were 40 to 80 years old, with a mean
of 64 years. Ten had been diagnosed with breast cancer,
seven with lung cancer, three with pancreatic cancer, and
one with esophageal cancer. All participants except one,
who was receiving hormone therapy, were undergoing
chemotherapy at the time of the interview. Nineteen par-
ticipants had been receiving the cancer treatment less
than 1 month, one participant for 1 to 3 months, and one
participant for more than 12 months. The Eastern
Cooperative Oncology Group (ECOG) performance status
was 0 for 9 participants, 1 for 8 participants, 2 for 2 partic-
ipants, and 3 for 2 participants. The participants took an
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average of 30 min to complete the questionnaires of ap-
proximately 61 items; skip patterns were not employed.
Table 2 lists the questionnaire items, showing the pro-
portion of patients who evaluated each PRO-CTCAE
item as “difficult to understand” and “difficult to answer”
respectively. The patients self-completed 45 items with-
out any difficulties; 33 items were evaluated as “difficult
to understand,” and 65 as “difficult to answer.” Only one
PRO-CTCAE item (anxiety severity) was found to be
“difficult to understand” by more than 20% of the
respondents. Eight items were evaluated as “difficult to
answer” by more of 20% of the respondents; three of these
were items related to sexual activities, such as “decreased
sexual interest,” “unable to have an orgasm or climax,”
and “took too long to have an orgasm or climax.”
Analyzing the 94 narrative comments provided on the
items across the debriefing interviews, 11 remarks con-
cerned comprehension difficulties, 13 remarks concerned
clarity, 25 remarks concerned knowledge and recall (ease
of memory retrieval), and 45 remarks concerned ease of
judgment or spontaneous comments. These remarks thus
applied to 52 out of the 123 items, with 71 items not
remarked on. Patients found it difficult to interpret some
symptoms, such as “body odor” (5 remarks) or “problems
with memory” (2 remarks), because their effects are rela-
tively subjective. Determining the severity of persistent
symptoms such as “anxiety” (4 remarks) or “leg/arm swel-
ling” (1 remark) was also problematic for small numbers
of participants. Problems determining whether something
like “aching joints” included symptoms such as stiff shoul-
ders or aching muscles were reported by five patients.
The following remarks related to the symptom attri-
bute (40 remarks) in the questionnaire were categorized:
no evaluation criteria are given (5 remarks), need for
benchmark (6 remarks), difficulty choosing only one
response (4 remarks), distinction between response
options is ambiguous (7 remarks), response options are
inadequate (6 remarks), questions and response options
need to be reformed (7 remarks), and inconsistency be-
tween questions and response options (4 remarks), and
other (1 remarks). The following remarks related to ease
of memory retrieval and judgment (26 remarks) were
categorized: some symptoms are hard to notice (6 re-
marks), need for exemplars of symptoms (10 remarks),
significance of the question should be clarified (3 re-
marks), problems interpreting “interference with daily
activities” (4 remarks), and problems apprehending the
severity of symptoms at their worst (3 remarks). Other
remarks on the questionnaire include the phrase “in the
last 7 days,” which complicated questions (5 remarks).
Participants with constant subjective symptoms in
particular seemed to find it challenging to confine the
interpretation of their symptom experience to only the
severity or interference experienced “in the last 7 days.”
Regarding the two alternative wordings of “its worst,” the
responses were varied among responders and symptoms.
Following agreement on changes among the project team,
ultimately we kept the initial wording, which is the object-
ive term discussed above, in the final version.
Table 1 Patient characteristics
Characteristics N = 21 (%)
Gender (n, %)
Male 6 (29%)
Female 15 (71%)
Age in years, mean (SD, range) 64 (11.2, 40–80)
Recruitment site (n, %)
The University of Tokyo Hospital 11 (52%)
Kansai Medical University Hospital 10 (48%)
Primary lesion (n, %)
Breast 10 (48%)
Lung 7 (33%)
Pancreatic 3 (14%)
Esophageal 1 (5%)
Progression (n, %)
Localized 3 (14%)
Metastatic 18 (86%)
ECOG Performance Status (n, %)
Grade 0 9 (43%)
Grade 1 8 (38%)
Grade 2 2 (10%)
Grade 3 2 (10%)
Treatment modality (n, %)
Chemotherapy 20 (95%)
Hormone therapy 1 (5%)
Treatment time (n, %)
within 1 month 19 (90%)
1–3 months prior 1 (5%)
12 months prior 1 (5%)
Employment (n, %)
Employed 3 (14%)
Housewife 10 (48%)
Unemployed 6 (29%)
Others 2 (10%)
Education
Junior high school 7 (33%)
High school 5 (24%)
Junior college 6 (29%)
Undergraduate/postgraduate 3 (14%)
Questionnairea completion time in
minutes, mean (SD, range)
30 (11.5, 15–58)
a61 items on average (minimum 50, maximum 68)
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Table 2 Proportion of patients who evaluated items as “difficult to understand” or “difficult to answer”
Items Dimension Difficult to understand Difficult to answer
n/N % n/N %
ACHING JOINTS Frequency 0/10 0/10
ACHING JOINTS Severity 0/10 1/10 10.0%
ACHING JOINTS Interference 0/10 1/10 10.0%
ACHING MUSCLES Frequency 0/10 0/10
ACHING MUSCLES Severity 0/10 1/10 10.0%
ACHING MUSCLES Interference 0/10 1/10 10.0%
ACNE OR PIMPLES ON THE FACE OR CHEST Severity 2/10 20.0% 1/10 10.0%
ANXIETY Frequency 1/11 9.1% 1/11 9.1%
ANXIETY Severity 3/11 27.3% 3/11 27.3%
ANXIETY Interference 1/11 9.1% 2/11 18.2%
ARM OR LEG SWELLING Frequency 0/16 1/16 6.3%
ARM OR LEG SWELLING Severity 0/11 2/11 18.2%
ARM OR LEG SWELLING Interference 0/11 2/11 18.2%
BED SORES Presence 0/11 0/11
BLOATING OF THE ABDOMEN (BELLY) Frequency 0/10 0/10
BLOATING OF THE ABDOMEN (BELLY) Severity 0/10 1/10 10.0%
BLURRY VISION Severity 0/10 3/10 30.0%
BLURRY VISION Interference 0/10 0/10
BODY ODOR Severity 1/11 9.1% 3/11 27.3%
BREAST AREA ENLARGEMENT OR TENDERNESS Severity 0/10 0/10
BRUISE EASILY (BLACK AND BLUE MARKS) Presence 0/10 2/10 20.0%
CHANGE IN THE COLOR OFYOUR FINGERNAILS OR TOENAILS Presence 0/11 0/11
CONSTIPATION Severity 0/11 1/11 9.1%
COUGH Severity 0/11 0/11
COUGH Interference 0/11 1/11 9.1%
DECREASED APPETITE Severity 0/11 0/11
DECREASED APPETITE Interference 1/11 9.1% 3/11 27.3%
DECREASED SEXUAL INTEREST Severity 0/10 5/10 50.0%
DIFFICULTY GETTING OR KEEPING AN ERECTION Severity 0/6 0/6
DIFFICULTY SWALLOWING Severity 0/11 1/11 9.1%
DIZZINESS Severity 0/11 0/11
DIZZINESS Interference 0/11 1/11 9.1%
DRY MOUTH Severity 0/11 0/11
DRY SKIN Severity 0/10 1/10 10.0%
EJACULATION PROBLEMS Presence 1/6 16.7% 0/6
FATIGUE, TIREDNESS, OR LACK OF ENERGY Severity 0/11 0/11
FATIGUE, TIREDNESS, OR LACK OF ENERGY Interference 1/11 9.1% 1/11 9.1%
FEEL THAT NOTHING COULD CHEER YOU UP Frequency 0/11 1/11 9.1%
FEEL THAT NOTHING COULD CHEER YOU UP Severity 1/11 9.1% 1/11 9.1%
FEEL THAT NOTHING COULD CHEER YOU UP Interference 1/11 9.1% 1/11 9.1%
FLASHING LIGHTS IN FRONT OF YOUR EYES Presence 0/10 0/10
FREQUENT URINATION Frequency 0/11 0/11
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Table 2 Proportion of patients who evaluated items as “difficult to understand” or “difficult to answer” (Continued)
FREQUENT URINATION Interference 0/11 1/11 9.1%
HAIR LOSS Amount 1/11 9.1% 1/11 9.1%
HAND-FOOT SYNDROME Severity 0/11 0/11
HEADACHE Frequency 0/11 0/11
HEADACHE Severity 0/11 1/11 9.1%
HEADACHE Interference 0/11 1/11 9.1%
HEARTBURN Frequency 0/10 0/10
HEARTBURN Severity 0/10 1/10 10.0%
HICCUPS Frequency 0/11 0/11
HICCUPS Severity 0/11 1/11 9.1%
HIVES (ITCHY RED BUMPS ON THE SKIN) Presence 1/10 10.0% 0/10
HOARSE VOICE Severity 1/11 9.1% 0/11
HOT FLASHES Frequency 1/10 10.0% 1/10 10.0%
HOT FLASHES Severity 1/10 10.0% 1/10 10.0%
INCREASED PASSING OF GAS (FLATULENCE) Presence 0/10 1/10 10.0%
INCREASED SKIN SENSITIVITY TO SUNLIGHT Presence 1/10 10.0% 0/10
INSOMNIA Severity 0/11 1/11 9.1%
INSOMNIA Interference 0/11 0/11
MISS AN EXPECTED MENSTRUAL PERIOD Presence 0/5 1/5 20.0%
IRREGULAR MENSTRUAL PERIODS Presence 0/5 0/5
ITCHY SKIN Severity 1/11 9.1% 0/11
LOOSE OR WATERY STOOLS (DIARRHEA) Frequency 0/11 1/11 9.1%
LOSE ANY FINGERNAILS OR TOENAILS Presence 1/10 10.0% 1/10 10.0%
LOSS OF CONTROL OF BOWEL MOVEMENTS Frequency 0/10 0/10
LOSS OF CONTROL OF BOWEL MOVEMENTS Interference 0/10 0/10
LOSS OF CONTROL OF URINE (LEAKAGE) Frequency 0/11 1/11 9.1%
LOSS OF CONTROL OF URINE (LEAKAGE) Interference 0/11 1/11 9.1%
MOUTH OR THROAT SORES Severity 0/11 0/11
MOUTH OR THROAT SORES Interference 0/11 1/11 9.1%
NAUSEA Frequency 0/11 0/11
NAUSEA Severity 0/11 1/11 9.1%
NOSEBLEEDS Frequency 0/10 0/10
NOSEBLEEDS Severity 0/10 0/10
NUMBNESS OR TINGLING IN YOUR HANDS OR FEET Severity 1/11 9.1% 1/11 9.1%
NUMBNESS OR TINGLING IN YOUR HANDS OR FEET Interference 1/11 9.1% 0/11
PAIN Frequency 0/11 1/11 9.1%
PAIN Severity 0/11 2/11 18.2%
PAIN Interference 0/11 2/11 18.2%
PAIN DURING VAGINAL SEX Severity 0/5 0/5
PAIN IN THE ABDOMEN (BELLY AREA) Frequency 0/11 0/11
PAIN IN THE ABDOMEN (BELLY AREA) Severity 0/11 1/11 9.1%
PAIN IN THE ABDOMEN (BELLY AREA) Interference 0/11 1/11 9.1%
PAIN OR BURNING WITH URINATION Severity 0/10 0/10
PAIN, SWELLING, OR REDNESSAT A SITE OF DRUG INJECTION OR IV Presence 0/11 0/11
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Discussion
This study was conducted following rigorous procedures
for translation and linguistic validation [20]. Although
the methodologies used were consistent with other
translations of PRO-CTCAE, our sample was relatively
small compared to those of other linguistic validation
studies [13–15]. However, the study population partially
represents the clinical, socioeconomic, and geographic
diversities in the general Japanese cancer population.
Moreover, there were no missing data, and the feasibility
of the measurements was confirmed.
In total, 33 items were evaluated as “difficult to under-
stand” and 65 items were evaluated as “difficult to an-
swer” by one or more participants when the participants
completed the questionnaire independently. However,
when we asked them about these items in the interviews,
Table 2 Proportion of patients who evaluated items as “difficult to understand” or “difficult to answer” (Continued)
POUNDING OR RACING HEARTBEAT (PALPITATIONS) Frequency 0/10 1/10 10.0%
POUNDING OR RACING HEARTBEAT (PALPITATIONS) Severity 0/10 2/10 20.0%
PROBLEMS WITH CONCENTRATION Severity 1/11 9.1% 1/11 9.1%
PROBLEMS WITH CONCENTRATION Interference 1/11 9.1% 1/11 9.1%
PROBLEMS WITH MEMORY Severity 2/10 20.0% 1/10 10.0%
PROBLEMS WITH MEMORY Interference 1/10 10.0% 0/10
PROBLEMS WITH TASTING FOOD OR DRINK Severity 0/11 1/11 9.1%
RASH Presence 0/11 0/11
RIDGES OR BUMPS ON YOUR FINGERNAILSOR TOENAILS Presence 0/10 2/10 20.0%
RINGING IN YOUR EARS Severity 0/10 0/10
SAD OR UNHAPPY FEELINGS Frequency 0/11 1/11 9.1%
SAD OR UNHAPPY FEELINGS Severity 1/11 9.1% 2/11 18.2%
SAD OR UNHAPPY FEELINGS Interference 0/11 1/11 9.1%
SHIVERING OR SHAKING CHILLS Frequency 0/10 1/10 10.0%
SHIVERING OR SHAKING CHILLS Severity 0/10 0/10
SHORTNESS OF BREATH Severity 1/10 10.0% 0/10
SHORTNESS OF BREATH Interference 1/10 10.0% 0/10
SKIN BURNS FROM RADIATION Severity 0/10 4/10 40.0%
SKIN CRACKING AT THE CORNERS OF YOUR MOUTH Severity 1/10 10.0% 0/10
SPOTS OR LINES THAT DRIFT IN FRONT OF YOUR EYES (FLOATERS) Presence 0/10 0/10
STRETCH MARKS Presence 2/10 20.0% 0/10
SUDDEN URGES TO URINATE Frequency 1/10 10.0% 0/10
SUDDEN URGES TO URINATE Interference 1/10 10.0% 0/10
TOOK TOO LONG TO HAVE AN ORGASM OR CLIMAX Presence 0/10 4/10 40.0%
UNABLE TO HAVE AN ORGASM OR CLIMAX Presence 0/10 4/10 40.0%
UNEXPECTED DECREASE IN SWEATING Presence 1/10 10.0% 1/10 10.0%
UNEXPECTED OR EXCESSIVE SWEATINGDURING THE DAY OR NIGHTTIME Frequency 0/10 0/10
UNEXPECTED OR EXCESSIVE SWEATINGDURING THE DAY OR NIGHTTIME Severity 0/10 0/10
UNUSUAL DARKENING OF THE SKIN Presence 0/10 0/10
UNUSUAL VAGINAL DISCHARGE Presence 0/5 0/5
URINE COLOR CHANGE Presence 0/10 0/10
VOICE CHANGES Presence 0/10 0/10
VOMITING Frequency 0/10 0/10
VOMITING Severity 0/10 0/10
WATERY EYES (TEARING) Severity 1/10 10.0% 1/10 10.0%
WATERY EYES (TEARING) Interference 0/10 0/10
WHEEZING Severity 0/10 0/10
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only 24 out of their 94 remarks were categorized as
relating to “comprehension difficulties” or issues with
“clarity.” For the qualitative analysis, we set the thresh-
old for consideration of rephrasing and testing of alter-
native phrasing at more than 20%. Table 3 shows the
remarks on the nine PRO-CTCAE items that were eval-
uated as “difficult to understand” or “difficult to answer”
by more than 20% of the respondents. Although some
remarks on “anxiety” were categorized as “clarity,” they
were related to the apprehension of symptomatic toxic-
ities in the context of attributes, such as “the severity of
anxiety at its worst.” Anxiety items were also found to
be challenging in Spanish PRO-CTCAE cognitive testing
[13]. Remarks on other items were mostly related to
problems with interpreting the symptom itself and
judging individual symptomatic events. Nevertheless,
we concluded that there was a good general under-
standing of these items, so no amendments to the
Japanese translated version were required after the
cognitive interviews.
Items related to sexual activities, such as “decreased
sexual interest,” “unable to have an orgasm or climax,”
and “took too long to have an orgasm or climax,” were
evaluated as “difficult to answer” by more than 40% of
patients. Moreover, “unable to have an orgasm or
climax” was remarked on only once, and “took too long
to have an orgasm or climax” was not remarked on at
all, even though a high proportion of patients evaluated
them as “difficult to answer.” This may have been
because Japanese patients tend to be hesitant about
answering questions regarding sexual activities [22]. The
lack of remarks on these items could also have been
influenced by gender non-concordance between study
participants and interviewers.
As discussed above, the patients comprehended the
questions and response items well in general. However,
interpreting symptoms using given response options was
confusing for some. For example, three patients had
issues with the severity-related wording “at its worst.”
Chronic symptoms seemed to be especially difficult to
evaluate in this regard. There were opinions that the
inclusion of “mild” as a response option was not
consistent with asking about the severity of a symp-
tom “at its worst.” Similar finding with severity items
were reported in cognitive interviews in an adolescent
population in USA [11]. Considering remarks on the
questionnaire such as “need for a benchmark” or “distinc-
tion among response options is ambiguous,” it is clear that
some patients find it difficult to respond using abstract
terminology instead of clear benchmarks, which may
Table 3 PRO-CTCAE items evaluated as “difficult to understand” or “difficult to answer” by more than 20% of patients and their
remarks
Item Attribute Patients with
difficulty (%)
No. of
remarks
codeda
Compre
hension
Clarity Knowledge/
recall
Ease of
judgment
Examples of patient remarks
Evaluated as “difficult to understand” by >20% of patients
Anxiety Severity 3/11 (27%) 6 – 2 3 2 Cannot apprehend severity of worst anxiety
Evaluated as “difficult to answer” by >20% of patients
Anxiety Severity 3/11 (27%) 6 – 2 3 2 To know my anxiety at its worst is difficult
due to ambiguous and constant nature of
symptom
Blurry
visionb
Severity 3/10 (30%) 0 . . . . –
Body odor Severity 3/11 (27%) 5 . . 5 . I am not sure if I should give my own
evaluation or third-person’s evaluation
Decreased
appetite
Interference 3/11 (27%) 2 – . 2 . Hard to imagine a situation where
decreased appetite interferes with daily
activities
Decreased
sexual interest
Severity 5/10 (50%) 4 . . 1 3 Unsure if decreased sexual interest resulting
from the aging process should be included
Skin burns
from radiationb
Severity 4/10 (40%) 0 . . . . –
Unable to
orgasm/climax
Presence 4/10 (40%) 1 . . . 1 This is a question for patients on lower
stages, not for those on 4th stage
Took too
long to climaxb
Presence 4/10 (40%) 0 . . . . –
aMultiple remarks could be coded from a single patient
bSeveral items elicited no remarks in interviews even though they were evaluated as difficult to understand or answer in the initial investigation
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reflect the sociocultural matter of Japanese respondents’
limited experience with patient-reported outcome mea-
surements in general rather than the Japanese translation.
Cultural differences exist in how Likert-type scales are
responded to, and Japanese people have frequently re-
ported difficultly doing so [23]. Also, 4 out of 6 remarks
on “need for a benchmark” were related to psychological
symptoms, including sleep, mood and memory, and
sensory aspects, and patients might have felt more diffi-
culty choosing options for these compared to other types
of symptoms. Nevertheless, the cognitive interviews
showed a good general understanding of most of the
items.
These study results should be interpreted with several
caveats in mind, including the small overall sample size,
the small number of respondents interviewed about each
item, and the possibility that the use of gender-
discordant interviewers may have made some partici-
pants reticent to discuss difficulties with PRO-CTCAE
items that reflect sexual functioning and genitourinary
symptoms. Also, we could not include Japanese-speaking
cancer patients living in the USA, who were part of the
target population of this questionnaire in the study.
These caveats notwithstanding, this study provides
preliminary evidence supporting the linguistic validity
of the Japanese language version of PRO-CTCAE.
These results should be confirmed and elaborated on
with further psychometric validation studies covering
construct validity, test–retest reliability, and sensitivity
to detect change; such studies are currently in pro-
gress as a part of the larger cross-cultural validation
of which this study is a part. The translation certifi-
cate was issued by the NCI, and the first version of
the Japanese translation is currently available through
the PRO-CTCAE website [7].
Conclusions
This study revealed that translation was conducted
using a rigorous process and the majority of the items
in the Japanese language version of PRO-CTCAE are
well understood by Japanese-speaking cancer patients.
The results provide preliminary evidence supporting
the linguistic and content validity of the Japanese
language version of PRO-CTCAE. However, further
cognitive interviews are needed for items related to
sexuality and to anxiety severity, as well as response
options for severity attribute items.
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